Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Neoadjuvant Therapy in NSCLC
NCT04646837Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04646837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646837.